Top

Reactions Weekly

Published in:

01-07-2022 | Infliximab | Case report

Adalimumab/infliximab

Thrombocytopenia and infusion reaction: 2 case reports

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Kunimi K, et al. Anti-TNF-alpha Therapy for Refractory Uveitis Associated with Behcet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients. Ocular Immunology and Inflammation 30: 223-230, No. 1, 2022. Available from: URL: http://www.tandfonline.com/loi/ioii20

Title: Adalimumab/infliximab
Thrombocytopenia and infusion reaction: 2 case reports
Publication date: 01-07-2022
Publisher: Springer International Publishing
Keywords: Infliximab
Uveitis
Adalimumab
Thrombocytopenia
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-18608-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Adalimumab/infliximab

Thrombocytopenia and infusion reaction: 2 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Bictegravir/emtricitabine/tenofovir-alafenamide

Abiraterone

DPP-4 inhibitors increase risk of cholecystitis

Ruxolitinib

Multiple drugs

Multiple drugs